Modification of brain lipids but not phenotype in α-synucleinopathy transgenic mice by long-term dietary n-3 fatty acids

Neurochemistry International

Volumn 56, Issue 2, 2010, Pages 318-328

  Muntané, Gerard ^a   Janué, Anna ^a   Fernandez, Nuria ^a   Odena, Maria Antonia ^c   Oliveira, Eliandre ^c   Boluda, Susana ^a   Portero Otin, Manuel ^b   Naudí, Alba ^b   Boada, Jordi ^b   Pamplona, Reinald ^b   Ferrer, Isidre ^a,c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF LLEIDA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Docosahexaenoic acid; Fatty acids; Oxidative stress; Parkinson disease; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; LINOLENIC ACID; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID;

ALPHA SYNUCLEINOPATHY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CELL LOSS; CONTROLLED STUDY; GLIOSIS; LEWY BODY; LIPID BRAIN LEVEL; LIPID COMPOSITION; LIPID DIET; MOUSE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 77149138801     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.10.015     Document Type: Article

References (56)

1. Baba M., Nakajo S., Tu P.H., Tomita T., Lee V.M., Trojanowski J.Q., Iwatsubo T. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 1998, 152:879-884.
2. Barceló-Coblijn G., Golovko M.Y., Weinhofer I., Berger J., Murphy E.J. Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. J. Neurochem. 2007, 101:132-141.
3. Barceló-Coblijn G., Högyes E., Kitajka K., Puskás L.G., Zvara A., Hackler L., Nyakas C., Penke Z., Farkas T. Modification by docosahexaenoic acid of age-induced alterations in gene expression and molecular composition of rat brain phospholipids. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:11321-11326.
4. Bouwens M., van de Rest O., Dellschaft N., Bromhaar M.G., de Groot L.C., Geleijnse J.M., Müller M., Afman L.A. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am. J. Clin. Nutr. 2009, 90:415-424.
5. Cabin D.E., Gispert-Sanchez S., Murphy D., Auburger G., Myers R.R., Nussbaum R.L. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. Neurobiol. Aging 2005, 26:25-35.
6. Calder P.C. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 2009, 91:791-795.
7. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., Rostaing P., Triller A., Salem N., Ashe K.H., Frautschy S.A., Cole G.M. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43:633-645.
8. Chesselet M.F. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?. Exp. Neurol. 2008, 209:22-27.
9. Dalfó E., Ferrer I. Early α-synuclein lipoxidation in neocortex in Lewy body diseases. Neurobiol. Aging 2008, 29:408-417.
10. Dalfó E., Portero-Otín M., Ayala V., Martínez A., Pamplona R., Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J. Neuropathol. Exp. Neurol. 2005, 64:816-830.
11. Dawson T., Mandir A., Lee M. Animal models of PD: pieces of the same puzzle?. Neuron 2002, 35:219-222.
12. Dickson D.W., Liu W., Hardy J., Farrer M., Mehta N., Uitti R., Mark, Zimmermann T., Golbe L., Sage J., Sima A., D'Amato C., Albin R., Gilman S., Yen S.H. Widespread alterations of alpha-synuclein in multiple system atrophy. Am. J. Pathol. 1999, 155:1241-1251.
13. Duda J.E., Giasson B.I., Chen Q., Gur T.L., Hurtig H.I., Stern M.B., Gollomp S.M., Ischiropoulos H., Lee V.M., Trojanowski J.Q. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol. 2000, 157:1439-1445.
14. Ebert S., Weigelt K., Walczak Y., Drobnik W., Mauerer R., Hume D.A., Weber B.H., Langmann T. Docosahexaenoic acid attenuates microglial activation and delays early retinal degeneration. J. Neurochem. 2009, 110:1863-1875.
15. Favrelière S., Perault M.C., Huguet F., De Javel D., Bertrand N., Piriou A., Durand G. DHA-enriched phospholipid diets modulate age-related alterations in rat hippocampus. Neurobiol. Aging 2003, 24:233-243.
16. Fernagut P.O., Chesselet M.F. Alpha-synuclein and transgenic mouse models. Neurobiol. Dis. 2004, 17:123-130.
17. Fetterman J.W., Zdanowicz M.M. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J. Health Syst. Pharm. 2009, 66:1169-1179.
18. Forno L. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1996, 55:259-272.
19. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. α-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell. Biol. 2002, 4:160-164.
20. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropuolos H., Trojanowski J.Q., Lee V.M.Y. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
21. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34:521-533.
22. Gispert S., Del Turco D., Garrett L., Chen A., Bernard D.J., Hamm-Clement J., Korf H.W., Deller T., Braak H., Auburger G., Nussbaum R.L. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol. Cell. Neurosci. 2003, 24:419-429.
23. Golovko M.Y., Barcelo-Coblijn G., Castagnet P.I., Austin S., Combs C.K., Murphy E.J. The role of α-synuclein in brain lipid metabolism: a downstream impact on brain inflammatory response. Mol. Cell. Biochem. 2008, 10.1007/s11010-008-0008-y.
24. Golovko M.Y., Rosenberger T.A., Faergeman N.J., Feddersen S., Cole N.B., Pribill I., Berger J., Nussbaum R.L., Murphy E.J. Acyl-CoA synthetase activity links wild-type but not mutant α-synuclein to brain arachidonate metabolism. Biochemistry 2006, 45:6956-6966.
25. Golovko M.Y., Rosenberger T.A., Feddersen S., Faergeman N.J., Murphy E.J. α-Synuclein gene ablation increases docosahexaenoic acid incorporation and turnover in brain phospholipids. J. Neurochem. 2007, 101:201-211.
26. Hashimoto M., Masliah E. α-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol. 1999, 9:707-720.
27. Haubner L.Y., Stockard J.E., Saste M.D., Benford V.J., Phelps C.P., Chen L.T., Barness L., Wiener D., Carver J.D. Maternal dietary docosahexanoic acid content affects the rat pup auditory system. Brain Res. Bull. 2002, 58:1-5.
28. Haubner L., Sullivan J., Ashmeade T., Saste M., Wiener D., Carver J. The effects of maternal dietary docosahexaenoic acid intake on rat pup myelin and the auditory startle response. Dev. Neurosci. 2007, 29:460-467.
29. Hulbert A.J., Pamplona R., Buffenstein R., Buttemer W.A. Life and death: metabolic rate, membrane composition, and life span of animals. Physiol. Rev. 2007, 87:1175-1213.
30. Iwatsubo T. Aggregation of α-synuclein in the pathogenesis of Parkinson's disease. J. Neurol. 2003, 250(Suppl. 3):11-14.
31. Jellinger K. Experimental models of synucleinopathies. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2003, 215-223. ISN Neuropath Press, Basel. D. Dickson (Ed.).
32. Jellinger K., Mizuno Y. Parkinson's disease. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2003, 159-187. ISN Neuropath Press, Basel. D. Dickson (Ed.).
33. Kitajka K., Puskas L.G., Zvara A., Hackler L., Barcelo-Coblijn, Yeo Y.K., Farkas T. The role of n-3 polyunsaturated fatty acids in brain: Modulation of rat brain gene expression by dietary n-3 fatty acids. Proc. Natl. Acad. Sci. U.S.A. 2009, 99:2619-2624.
34. Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J.T., Schöls L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
35. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:8968-8973.
36. Li W., West N., Colla E., Pletnikova O., Troncoso J.C., Marsh L., Dawson T.M., Jäkälä P., Hartmann T., Price D.L., Lee M.K. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2162-2167.
37. Liu X., Shibata T., Hisaka S., Kawai Y., Osawa T. DHA hydroperoxides as a potential inducer of neuronal cell death: a mitochondrial dysfunction-mediated pathway. J. Clin. Biochem. Nutr. 2008, 43:26-33.
38. Liu W., Wang H.J., Wang L.P., Liu S.L., Wang J.Y. Formation of high-molecular-weight protein adducts by methyl docosahexaenoate peroxidation products. Biochem. Biophys. Acta 2007, 1774:258-266.
39. Long E.K., Murphy T.C., Leiphon L.J., Watt J., Morrow J.D., Milne G.L., Howard J.R., Picklo M.J. Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22:6; n-3) acid oxidation. J. Neurochem. 2008, 105:714-724.
40. Michell A.W., Tofaris G.K., Gossage H., Tyers P., Spillantini M.G., Barker R.A. The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. Cell Transplant. 2007, 16:461-474.
41. Mohrhauer H., Holman R.T. Alteration of the fatty acid composition of brain lipids by varying levels of dietary essential fatty acids. J. Neurochem. 1963, 10:523-530.
42. Oksman M., Iivonen H., Hogyes E., Amtul Z., Penke B., Leenders I., Broersen L., Lütjohann D., Hartmann T., Tanila H. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis. 2006, 23:563-572.
43. Pamplona R., Ilieva E., Ayala V., Bellmunt M.J., Cacabelos D., Dalfo E., Ferrer I., Portero-Otin M. Maillard reaction versus other nonenzymatic modifications in neurodegenerative processes. Ann. N.Y. Acad. Sci. 2008, 1126:315-319.
44. Pamplona R., Dalfó E., Ayala V., Bellmunt M.J., Prat J., Ferrer I., Portero-Otín M. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J. Biol. Chem. 2005, 280:21522-21530.
45. Periquet M., Fulga T., Myllykangas L., Schollmacher M.G., Feany M.B. Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo. J. Neurosci. 2007, 27:3338-3346.
46. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
47. Riediger N.D., Othman R.A., Suh M., Moghadasian M.H. A systemic review of the roles of n-3 fatty acids in health and disease. J. Am. Diet Assoc. 2009, 109:668-679.
48. Saraswathy S., Wu G., Rao N.A. Retinal microglial activation and chemotaxis by docosahexaenoic acid hydroperoxide. Invest. Ophthalmol. Vis. Sci. 2006, 47:3656-3663.
49. Schults C.W. Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1661-1668.
50. Spillantini M.G., Schmidt M., Lee V.M., Trojanowski J.Q., Kaques R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
51. Tanito M., Brush R.S., Elliott M.H., Wicker L.D., Henry K.R., Anderson R.E. High levels of retinal membrane docosahexaenoic acid increase susceptibility to stress-induced degeneration. J. Lipid Res. 2008, (Nov 20). Epub ahead of print.
52. van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W.P., Ruegg M.A., Lin S., Caroni P., Sommer B., Tolnay M., Bilbe G. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 2000, 20:6021-6029.
53. Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto M., Takahashi H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett. 1997, 249:180-182.
54. Wakamatsu M., Ishiii A., Iwata S., Sakagami J., Ukai Y., Ono M., Kanbe D., Muramatsu S., Kobayashi K., Iwatsubo T., Yoshimoto M. Selective loss of nigral dopamine neurons induced by over-expression of truncated human α-synuclein in mice. Neurobiol. Aging 2008, 29:574-585.
55. Wang S., Wu D., Matthan N.R., Lamon-Fava S., Lecker J.L., Lichtenstein A.H. Reduction in dietary omega-6 polyunsaturated fatty acids: eicosapentaenoic acid plus docosahexaenoic acid ratio minimizes atherosclerotic lesion formation and inflammatory response in the LDL receptor null mouse. Atherosclerosis 2009, 204:147-155.
56. Zarranz J.J., Alegre J., Gómez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atarés B., Llorens V., Gomez Tortosa E., del Ser T., Muñoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.